Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors
The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic castrate-resistant prostate cancer, as well as those with several other immunologically cold tumors as part of the phase 1b/2 IMMCO-1 trial.
Jonathan Chatzkel University Of Florida Health University Of Florida Data Integrity Division Of Hematology University Of Florida College Medicine Safety Committee
Source: onclive.com